TTR and polyneuropathy: In this phase I clinical trial, six hATTR patients with polyneuropathy received NTLA-2001 injection, and 28 days later, circulating TTR levels were reduced in a dose-dependent manner, with an average of 52 and 87% TTR reduction in the lower-dose group and the higher-dose group, respectively (136).